TABLE 2

Clinical, hormonal, and metabolic features of women with PCOS (n = 21) before and after metformin treatment

Before metforminAfter metforminSignificance
Age (years)28 (26.5–31.5)28 (27.5–32.5)NS
BMI (kg/m2)32.8 (29.8–36.5)31.4 (28.2–35.1)NS
WHR0.82 (0.76–0.88)0.80 (0.74–0.87)P < 0.05
Glucose (mmol/l)5.1 (4.7–5.5)4.8 (4.4–4.9)P < 0.01
Insulin (pmol/l)70.0 (54.5–98.0)60.0 (43.5–81.0)NS
HOMA-IR2.1 (1.7–3.1)1.6 (1.3–2.3)P < 0.05
Cholesterol (mmol/l)4.9 (4.1–5.3)5.0 (4.0–5.4)NS
Triglycerides (mmol/l)1.0 (0.7–1.9)1.2 (1.0–1.7)NS
E2 (pmol/l)329.8 (164.9–494.7)207.1 (103.6–310.7)P < 0.05
Testosterone (nmol/l)1.8 (1.4–2.2)1.3 (1.0–1.8)P < 0.05
Androstenedione (nmol/l)10.9 (8.0–14.0)9.7 (7.6–12.4)NS
DHEA-S (μmol/l)4.4 (2.8–5.8)5.4 (3.6–6.7)NS
SHBG (nmol/l)27.0 (21.0–41.0)25.0 (20.5–46.5)NS
FAI6.2 (4.6–8.0)5.2 (3.1–6.6)NS
Leptin (ng/ml)26.5 (20.7–30.9)25.1 (17.9–30.0)NS
Adiponectin (μg/ml)4.85 (4.14–6.88)3.69 (2.91–5.55)NS
Chemerin (ng/ml)6.36 (5.80–6.83)2.19 (2.04–4.02)P < 0.01
  • Data are medians (interquartile range). Group comparison by Mann-Whitney U test. FAI = Testosterone (nmol/liter)/SHBG (nmol/liter) × 100. NS = not significant. FAI, free androgen index; SHBG, sex hormone–binding globulin.